Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.
Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The
aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically
ill patients with COVID-19. Patients admitted to the intensive care unit, with COVID-19 are
examined with echocardiography for assessment of left and right ventricular dysfunction
within 72 hours from admission and repeated after four to seven days.
Cardiac dysfunction was defined as having either left ventricular (LV) dysfunction, defined
as having an ejection fraction <50% and/or regional hypokinesia, or right ventricular (RV)
dysfunction, defined as having a tricuspid annular plane excursion (TAPSE) <17mm or a
moderate/severe RV dysfunction assessed visually.
The cardiac biomarkers troponin and NTproBNP and clinical data are recorded at time of each
echo. Mortality status is recorded at 30 days.
Diagnostic Test: Echocardiography
Echocardiography for assessment of cardiac function
Inclusion Criteria: Patients admitted to the intensive care unit infected with COVID-19
Exclusion Criteria:
-
Södersjukhuset
Stockholm, Region Stockholm, Sweden
North Älvsborg County Hospital
Trollhättan, Västra Götalandsregionen, Sweden
Sahlgrenska University Hospital/Mölndal
Gothenburg, Västra Götaland, Sweden
Sahlgrenska University Hospital/Östra
Gothenburg, Västra Götaland, Sweden
Sahlgrenska University Hospital
Gothenburg, Västra Götaland, Sweden
Jonatan Oras, MD, PhD, Principal Investigator
Sahlgrenska University Hospital, Sweden